Journal profile · Medicine-Dermatology
JID Innovations
ISSN 2667-0267 · Elsevier · United States
JID Innovations: impact factor 3 (journal website); fully open access; APC about USD 2,200; median 158 days to acceptance (96 articles, last 24 months); acceptance rate 72% (journal website); 88 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
JID Innovations is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are Dermatology and Skin Diseases, Psoriasis: Treatment and Pathogenesis and Skin Protection and Aging, together about 32.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Skin Science from Molecules to Population HealthJID Innovations is an online-only Open Access journal that provides an international forum for the publication of high-quality, peer reviewed research in the field of skin biology and disease. JID Innovations features original scientific reports related to all aspects of skin science from molecular studies to population health, including studies addressing the pathogenesis and treatment of skin diseases. Submissions should address questions that are important and relevant to the community of researchers and clinicians focused on skin biology and disease. Submissions may confirm or challenge current knowledge, inform the community of a new technology or resource, advance a new hypothesis, or challenge existing paradigms.JID Innovations invites submission of original scientific articles, clinical trial reports, case reports and case series, descriptions of methods and new technologies, reviews, and letters to the Editor.The scope of JID Innovations is by design broad. As our subtitle - "Skin science from molecules to population health" - suggests, we will publish articles on all aspects of skin biology and pathology. We are interested in molecular mechanisms and population health. We will be soliciting review articles with a focus on what experiments need to be done, looking forward, not back. We will be interested both in studies that close knowledge gaps and those that expose gaps in our current thinking. We will also seek descriptions of new methods that have great potential in the investigation of skin and skin diseases. We will pursue studies that stimulate and guide future studies; molecular studies that suggest new therapeutic interventions; as well as small clinical trials that provide potentially critical clues for mechanisms of disease.So-called negative studies that address important questions and are well done are important in formulating future hypotheses, and they are welcome. Clinical trials on small, localized populations help researchers move towards larger definitive trials more quickly; JID Innovations welcomes these submissions as well. Well-done studies that contradict current dogma can open the scientific community's eyes to new paradigms, and these are also welcome.JID Innovations is committed to the principle that timely, barrier-free circulation of ideas is the best way to advance understanding.All submissions to JID Innovations will be subject to rigorous peer review, and all authors will be expected to make their data available for replications through an established data repository or through the authors. Authors who cannot comply with these requirements should not submit their work to JID Innovations .Queries can be directed to the Editor at InnovationsEditor@sidnet.org.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Dermatology
Editor-in-chief Cristina de Guzman StrongPublisher website
Editorial board by country: 4 in mainland China (about 10%); most named United States 21, United Kingdom 5, Mainland China 4, Taiwan, China 2, Japan 2 (40 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Dermatology and Skin DiseasesMedicine18.3%
- Psoriasis: Treatment and PathogenesisImmunology and Microbiology8.1%
- Skin Protection and AgingMedicine6%
- Cutaneous Melanoma Detection and ManagementMedicine5.8%
- Autoimmune Bullous Skin DiseasesMedicine5.2%
- Nonmelanoma Skin Cancer StudiesMedicine4.4%
- Skin and Cellular Biology ResearchBiochemistry, Genetics and Molecular Biology4.1%
- Wound Healing and TreatmentsMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3Publisher website ·
- CiteScore 2026-06
- 6.6LetPub ·
- CiteScore (publisher)
- 6.6Publisher website ·
- SJR 2026-06
- 1.24LetPub ·
- SNIP 2026-06
- 1.2LetPub ·
- h-index
- 27OpenAlex ·
- i10-index
- 94OpenAlex ·
- 2-year mean citedness
- 2.15OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 99.51%LetPub ·
Volume
- Articles per year
- 76LetPub ·
Articles by year OpenAlex count · 490 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 88 | 88 | 20 |
| 2025 | 88 | 88 | 159 |
| 2024 | 82 | 82 | 375 |
| 2023 | 67 | 67 | 610 |
| 2022 | 76 | 76 | 1,113 |
| 2021 | 89 | 89 | 1,340 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
158 daysMedian, submission to acceptance · P25–P75 120 days – 210 days
- Acceptance to online
- median 18 days (96 articles)
- Submission to online
- median 180 days
- Sample
- 96 articles with submission and acceptance dates (179 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 8 weeksLetPub ·
- Acceptance rate (publisher)
- 72%Publisher website ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,200 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 2,000 / EUR 1,870 / GBP 1,600 / JPY 248,060 | — | — | |
| LetPub | USD 2,000 | Yes | — | |
| Publisher website | USD 1,500 / USD 2,000 | — | — |
Other charges and waivers (author guidelines)
- Submission fee
- USD 1,500
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- ≤ 200 words
- Manuscript length
- ≤ 3,500 words
- Reference style
- Author–date
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional, 4
- Highlights
- Required
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted7
- case reportCase reports and series which describe preferably 3 or more patients will be considered for JID Innovations. These reports should provide new and important obse…Length not stated
- letterBelow please find requirements for revised articles submitted to JID Innovations.Original Article:Present original research. Investigative studies should be org…Length not stated
- letter to the editorDiscussions of published articles. (All reports of original data should be submitted as Original Articles.) Letters should be organized as follows: Title page, …Length not stated
- original articleBelow please find requirements for revised articles submitted to JID Innovations.Original Article:Present original research. Investigative studies should be org…Length not stated
- original researchBelow please find requirements for revised articles submitted to JID Innovations.Original Article:Present original research. Investigative studies should be org…Length not stated
- reviewBelow please find requirements for revised articles submitted to JID Innovations.Original Article:Present original research. Investigative studies should be org…Length not stated
- review articleComprehensive, scholarly, and balanced, presenting an expert curation of the literature in the topic of interest. Consult the Editor at [email protected] before…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Preprints, Self-archiving, Trial registration / reporting guidelines
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Authorship Conditions
JID Innnovations ascribes to the authorship guidelines described in the The Uniform Requirements for Manuscripts Submitted to Biomedical Journals, by the International Committee of Medical Journal Editors. Briefly, each author should have participated sufficiently in the intellectual content of the work to take public responsibility for appropriate portions of its content. Authorship credit should…
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest
Upon submission, the corresponding author will receive a unique link to an online form on which they will be asked to declare qualifications for authorship and any conflicts of interest FOR ALL AUTHORS. More information on conflict of interest can be found on the form and in The Uniform Requirements for Manuscripts Submitted to Biomedical Journals, by the International Committee of Medical Journal…
Source ↗Publisher website ·- Data availability Data Availability Statement
The Editors seek to facilitate research progress, allow for reproducibility of results, and enhance replicability of findings in published research. To that end, primary research data should be made available free of charge to all researchers, whenever possible, and with minimal reuse restrictions. All submissions must include a "Data Availability Statement" that describes the availability of the …
Source ↗Publisher website ·- License & copyright Copyright
Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (see more information on this). Permitted third party reuse of open access articles is determined by the author's choice of user license.Author rightsAs an author you (or your employer or institution) have certain rights to reuse your work. More information.
Source ↗Publisher website ·- Open access Open Access
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Peer review Peer Review
Double-anonymized peer review for all new submissions received on or after 31 October 2022. Model summary
JID Innovations employs ScholarOne Manuscripts to conduct double-anonymized peer review. Under double-anonymized peer review, authors' identities are not disclosed to the reviewers -- and reviewers' identities are not disclosed to the authors. This process is intended to provide a fairer review for submitting authors, as described in this editorial.Authors may suggest the invitation or exclusion o…
Source ↗Publisher website ·- Preprints Preprints
Preprint postings on a not-for-profit website such as bioRxiv will not constitute prior publication as it relates to eligibility for consideration for publication in JID Innovations. Although eligibility for consideration for publication in JID Innovations will not be compromised by preprint posting, it is possible that the novelty of any submission could be diminished if widespread publicity is a…
Source ↗Publisher website ·- Self-archiving Embargo Policy
All articles accepted for publication in JID Innovations are embargoed until the date of online publication.For Original Articles and Letters to the Editor, both of which are published online before copyediting and typesetting, the following guidelines apply. The publication of the accepted manuscript online is an official publication of a JID Innovations article. It is a .pdf of the accepted vers…
Source ↗Publisher website ·- Trial registration / reporting guidelines Reporting Guidelines:
Specific categories are preferred over collective terms, when possible. Authors should report the specific categories used in their studies and recognize that these categories will differ based on the databases or surveys used, the requirements of funders, and the geographic location of data collection or study participants. Categories included in groups labeled as “other” should be defined. Categ…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United States
- Language
- English
- ISSN
- 2667-0267
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about JID Innovations
What is the impact factor of JID Innovations?
The journal's website gives an impact factor of 3; this is the journal's own figure, as LetPub lists none for it; CiteScore 6.6, h-index 27.
How long does peer review take at JID Innovations?
Based on the dates recorded on 96 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 158 days (interquartile range 120–210 days); authors report an average review time of about 8 weeks; the journal's website gives an acceptance rate of 72%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of JID Innovations?
According to the journal's author guidelines: Abstract: ≤ 200 words; Manuscript length: ≤ 3,500 words; Reference style: Author–date; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional, 4; Highlights: Required; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of JID Innovations based?
Of the 40 board members whose country the journal's board page names, 4 (about 10%) are in mainland China; the countries named most often are United States (21), United Kingdom (5) and Mainland China (4). Counted from the institutions listed on the board page; for reference only.
Which databases index JID Innovations?
According to LetPub and DOAJ records, JID Innovations is indexed in ESCI, Scopus and DOAJ.
Is JID Innovations open access, and what is the APC?
JID Innovations is a fully open-access journal. APC about USD 2,200.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .